

193701
RECORD NO.

122804
SHAUGHNESSEY NO.

REVIEW NO.

EEB REVIEW

DATE: IN 04-16-87 OUT 04-20-87

FILE OR REG. NO 50658-EUP-1

DATE OF SUBMISSION 04-14-87

DATE RECEIVED BY HED 04-16-87

RD REQUESTED COMPLETION DATE 05-18-87

EEB ESTIMATED COMPLETION DATE 05-18-87

RD ACTION CODE/TYPE OF REVIEW 711

TYPE PRODUCT(S) : I, D, H, F, N, R, S Insecticide

DATA ACCESSION NO(S).

PRODUCT MANAGER NO. G. LaRocca (41)

PRODUCT NAME Avermectin

COMPANY NAME Merck and Company, Incorporated

SUBMISSION PURPOSE Revised Label and Section G in

Compliance with Endangered Species

Concerns



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

OFFICE OF
PESTICIDES AND TOXIC SUBSTANCES

MEMORANDUM

APR 20 1987

SUBJECT: Review of Modified EUP for Avermectin on Citrus

FROM: *Daniel Rieder 4/20/87*
Daniel Rieder, Wildlife Biologist
Ecological Effects Branch
Hazard Evaluation Division

THRU: Norman J. Cook, Head, Section 2 *Norman J. Cook 4.20.87*
Ecological Effects Branch
Hazard Evaluation Division

THRU: Michael W. Slimak, Chief *M. Slimak 4/21/87*
Ecological Effects Branch
Hazard Evaluation Division TS-769C

TO: George LaRocca (PM 15)
Insecticides/Herbicides Branch
Registration Division TS-767C

The Ecological Effects Branch has reviewed the modified Section G of the 50658-EUP-1 submitted by Merck and Company, Inc. The EUP was previously reviewed by D. Rieder (2/26/87). The conclusion was that, among other things, Avermectin could not be used in Florida because of concerns to Endangered Species.

In this submission, Merck has provided information obtained in consultation with the Jacksonville, FL Office of Endangered Field Station, USFWS. This information indicates the areas where Avermectin will not be applied during this EUP. See the attached Section G2, Restrictions. Avoiding these areas eliminates potential effects to the species identified in the 2/26/87 review.

On 4/10/87, Linda Walker (8-946-2580) of the Jacksonville, FL OES Field Office called me and confirmed that Merck representatives had met with her on 4/6/87 and together they were able to identify areas to be avoided during this EUP to protect endangered species. She further indicated that the Section G copy she received accurately reflected the agreements reached at that meeting.

The EEB therefore concludes that conducting this EUP (50658-EUP-1) in Florida will not affect endangered species.

MEMORANDUM

APR 20 1987

SUBJECT: Review of Modified EUP for Avermectin on Citrus

FROM: Daniel Rieder, Wildlife Biologist
Ecological Effects Branch
Hazard Evaluation Division

THRU: Norman J. Cook, Head, Section 2
Ecological Effects Branch
Hazard Evaluation Division

THRU: Michael W. Slimak, Chief
Ecological Effects Branch
Hazard Evaluation Division TS-769C

TO: George LaRocca (PM 15)
Insecticides/Herbicides Branch
Registration Division TS-767C

The Ecological Effects Branch has reviewed the modified Section G of the 50658-EUP-1 submitted by Merck and Company, Inc. The EUP was previously reviewed by D. Rieder (2/26/87). The conclusion was that, among other things, Avermectin could not be used in Florida because of concerns to Endangered Species.

In this submission, Merck has provided information obtained in consultation with the Jacksonville, FL Office of Endangered Field Station, USFWS. This information indicates the areas where Avermectin will not be applied during this EUP. See the attached Section G2, Restrictions. Avoiding these areas eliminates potential effects to the species identified in the 2/26/87 review.

On 4/10/87, Linda Walker (8-946-2580) of the Jacksonville, FL OES Field Office called me and confirmed that Merck representatives had met with her on 4/6/87 and together they were able to identify areas to be avoided during this EUP to protect endangered species. She further indicated that the Section G copy she received accurately reflected the agreements reached at that meeting.

The EEB therefore concludes ~~concurrent~~ conducting this EUP

SYMBOL	50658-EUP-1	TS-769C	TS-769C	TS-769C	TS-769C	TS-769C	TS-769C	TS-769C
SURNAME	Rieder	Cook	Slimak					
DATE	4/20/87	4-20-87	4/21/87					

Avermectin science review

Page _____ is not included in this copy.

Pages 4 through 10 are not included in this copy.

The material not included contains the following type of information:

- ☐ Identity of product inert ingredients
 - ☐ Identity of product impurities
 - ☐ Description of the product manufacturing process
 - ☐ Description of product quality control procedures
 - ☐ Identity of the source of product ingredients
 - ☐ Sales or other commercial/financial information
 - ☐ A draft product label
 - ☐ The product confidential statement of formula
 - ☐ Information about a pending registration action
 - ☒ FIFRA registration data
 - ☐ The document is a duplicate of page(s) _____
 - ☐ The document is not responsive to the request
-

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.
